Biodexa Pharmaceuticals announces final match payment with respect to $17M grant

Biodexa Pharmaceuticals made the final match payment with respect to a $17 million grant from the Cancer Prevention Research Institute of Texas. Familial Adenomatous Polyposis is an inherited disease that causes the growth of hundreds or thousands of precancerous polyps throughout the GI tract, putting those afflicted at great risk of developing colon cancer. There is no approved therapeutic option for treating the approximately 100,000 FAP patients in the U.S. and Europe. The current standard of care is active surveillance and surgical resection of the colon and/or rectum. Results of a 12cmonth Phase 2 clinical trial of eRapa in FAP demonstrated a 17 per cent median decrease in overall polyp burden and an overall non-progression rate of 75 per cent. A Phase 3 registrational trial is expected to begin enrollment early next year.